Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
我们的信息全面覆盖商业、临床、监管与研发领域的关键事件，让您时刻掌握您的业务所处的竞争格局与前景。
To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our pharmaceutical competitive and market intelligence databases can give you all the credible, detailed information you need in one place.
What we offer
You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.
Build detailed competitive and market landscape analyses quickly, with access to global information on:
How it helps
We help you more accurately:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Real-time tracking and analysis of the drug development pipeline
Key benefits:
Scrip
By Ian Schofield 29 Nov 2022
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
Topic Cancer
Citeline, Trialtrove
25 Nov 2022
Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.
Topic Coronavirus
Scrip
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Datamonitor Healthcare
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
Scrip
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Scrip
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Datamonitor Healthcare
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topic Cancer
Datamonitor Healthcare
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Scrip
By Jung Won Shin 25 Oct 2022
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Topic Company Analysis Strategy
Scrip
20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Trialtrove
06 Oct 2022
Takes a deep dive into the clinical trial landscape in the Asia-Pacific (APAC) region over the past decade, from 2012 to 2021. APAC has become a hotspot for clinical trials, with trial activity trending upwards and eventually contributing almost half of the entire global clinical trial activity in 2021
Biomedtracker, Meddevicetracker
23 May 2022
In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.
Topic Outlook
Biomedtracker, Meddevicetracker
08 Feb 2022
In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.
Topic Business Strategies
Trialtrove
02 Feb 2022
To highlight the growing importance of IO and especially IO combination trials within oncology clinical development, visual trends and key insights about the past 20+ years were compiled.
Scrip
By Scrip Team 18 Jan 2022
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.
Scrip
02 Jun 2023
Scrip
02 Jun 2023
Scrip
02 Jun 2023
Scrip
02 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
01 Jun 2023
Scrip
31 May 2023
Scrip
31 May 2023
Scrip
31 May 2023
Scrip
31 May 2023
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
报告商城
迫切需要某一领域的的全面信息？
不妨在我们的报告商城中搜索是否有符合您需求的相关报告—— 海量实用报告供您甄选。
